Synonym: 3,5-Diamino-4-(p-methoxyphenyl)hydrazonopyrazole; 4-((4-Methoxyphenyl)diazenyl)-1H-pyrazole-3,5-diamine; ILK-IN-3; KP 15792; KP-15792; KP15792; QLT 0267; QLT-0267
CAS Number: 6975-75-3
Empirical Formula (Hill Notation): C10H12N6O
Molecular Weight: 232.24
MDL Number: MFCD01239326
Linear Formula: C10H12N6O
Product Type: Chemical
| assay |
≥98% (HPLC) |
| color |
white to beige |
| form |
powder |
| Quality Level |
100  |
| solubility |
DMSO: 2 mg/mL, clear |
| storage temp. |
2-8°C |
| Biochem/physiol Actions: |
QLT0267 is an orally active, potent and selective integrin-linked kinase (ILK) inhibitor (IC50 = 26 nM; selectivity: >1000-fold over CK2, CSK, DNA-PK, PIM1, PKB/AKT, PKC, >100-fold over ERK1, GSK3β, LCK, PKA, p70S6K, and RSK1/QLT, >10-fold over CDK1/2/5) that inhibits ILK-dependent cellular signaling (IC50 in 2h = 1 μM against 20 nM EGF-induced pAKT Ser473 phosphorylation in Hth74 cells). QLT0267 treatment causes thyroid cancer cell cycle arrest and apoptosis, leading to anti-proliferation efficacy in cultures (IC50 <6 μM; NPA187, DRO, and K4 cell lines) and in mice in vivo (DRO xenografts-derived tumor growth; 50-100 mg/kg via daily p.o.). |
| Purity |
≥98% (HPLC) |
| Storage Temp. |
2-8°C |
| UNSPSC |
12352200 |
